The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 62.50
Bid: 60.00
Ask: 65.00
Change: -0.50 (-0.79%)
Spread: 5.00 (8.333%)
Open: 63.00
High: 63.00
Low: 62.50
Prev. Close: 63.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EMV Capital Advises on £3.4m PointGrab Fundraise

20 May 2021 07:00

RNS Number : 1931Z
NetScientific PLC
20 May 2021
 

NetScientific plc

("NetScientific", the "Group" or the "Company")

 

EMV Capital advises on £3.4m funding for smart sensor maker PointGrab

 

London, UK - 20 May 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its corporate finance and venture capital division, EMV Capital Ltd ("EMVC") has advised on a £3.4m equity raise in PointGrab, a maker of smart sensors that help businesses maintain social distancing in post-COVID offices. The fundraise included a direct investment of £60,000 by NetScientific.

 

PointGrab's product is a smart workplace platform system enabling organisations to count, track the flow and locate people at individual desks, on floors or across an entire campus. It alerts users when social distancing measures are breached. The system also features cleaning and sanitation measures to help make offices COVID secure. The platform is already used in over 40 countries, by 45 Fortune 500 Companies.

With the return to the office now in sight, globally, employers are working on ways to help their teams return to work in safe environments that meet new COVID-secure working practices.

PointGrab's solution is well tried and tested, having been deployed in over 200 locations across five continents. It offers an immediate and integrated solution to the problems facing commercial real estate manager and companies in a post-COVID world. This funding will build on a solid pipeline of new deployments globally.

 

EMV Capital's syndicated investment will be used to address increasing requirements from PointGrab's new and existing clients to provide technological solutions to help people return to offices in a COVID-safe manner. This funding round includes investments from existing PointGrab investors, EMV Capital's parent company NetScientific PLC and new EMV Capital private investors.

 

Doron Shachar, CEO of PointGrab, said: "PointGrab will use this investment to consolidate our position as a leader in the growing smart office market segment, and continue to service Fortune 500 and other industry leader clients. Our platform enables creative and stress-free working environments by providing real-time data and flexibility to employers, compliant with new health and safety regulations. PointGrab is expanding to help its customers adjust to this new business landscape, accelerating the return to business as usual, while reducing public health risk."

 

Dr. Ilian Iliev, CEO of NetScientific commented: "As a long-term investor, we backed PointGrab management's vision of using smart technology for a safe, productive and flexible office environment. In line with our pro-active investment strategy, we worked with the management team throughout the COVID crisis to help evolve corporate and investment strategy in response to the once-in-a-generation shifts in corporate practices unleashed by COVID."

 

 

For more information, please contact:

 

NetScientific

Via Walbrook PR

Ilian Iliev, CEO 

 

 

 

WH Ireland (NOMAD, Financial Adviser and Broker)

 

Chris Fielding / Darshan Patel 

+44 (0)20 7220 1666

 

 

Walbrook PR

+44 (0)20 7933 8780 or netscientific@walbrookpr.com 

Nick Rome / Nicholas Johnson / Paul McManus

 

07748 325 236 / 07884 664 686 / 07980 541 893

 

 

 

About NetScientific

NetScientific plc (AIM: NSCI) is a holding company, that invests in, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies, which offer significant growth potential predominately in the UK and USA, as well as globally. 

With the acquisition of EMV Capital in August 2020, the Group doubled its portfolio from 8 to 17 companies, either through direct subsidiary, balance sheet investment or capital under advisory, varying from start-up private companies to publicly listed equities. 

NetScientific delivers shareholder returns through a proactive and hands-on management approach to their portfolio companies; identifying, investing in, and helping to build game-changing companies. The Group targets value inflection points and the release of value through partial or full exits from trade sales, public listings, or equity sales. The Company has a strong transatlantic and growing international presence, providing attractive expansion prospects. 

NSCI can deploy a capital-light investment structure; utilising the power of the PLC Brand, and the NetScientific balance sheet to anchor future investments and achieve a multiplier effect by attracting 3rd party investment for the portfolio companies. 

NetScientific is headquartered in London, United Kingdom, and was admitted to trading on AIM, a market operated by the London Stock Exchange, in 2013 (website: www.netscientific.net).

About PointGrab www.pointgrab.com

PointGrab is a leading machine learning and computer vision PropTech company that provides smart sensing solutions to the building automation and facilities management industry. The company applies its superior deep-learning technology to the building automation ecosystem, where opportunities to gather data are abundant, but efficient, real-time analytics are lacking. Its investors include EMV Capital, ABB Ventures, Signify, and various family offices.

 

For PointGrab COVID-19 use case video, please visit https://vimeo.com/407575381

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEKLFFFELLBBX
Date   Source Headline
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.